Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 0%
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Abpro Holdings, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease in the United States. Its platforms include DiversImmune, an antibody discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides flexibility to combine antibody building blocks in different combinations and orientations to create fit-for-purpose novel full-length multispecific antibody constructs. The company's lead product candidates include ABP-102, a next-generation immuno-oncology TetraBi antibody targeting HER2 and CD3 developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibits VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Ahmad Shahraab | Other | n/a (No price was disclosed in the filing) | SEC | ||
| Ahmad Shahraab |
| Other |
| n/a (No price was disclosed in the filing) |
| SEC |
| Kahlon Iqbaljit | Other | n/a (No price was disclosed in the filing) | SEC |
| Atlantic Coastal Acquisition Management II LLC | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Dove Bryan | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Atlantic Coastal Acquisition Management II LLC | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lord Joanna | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Kahlon Iqbaljit | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Schiano Dominick | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Kahlon Iqbaljit | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Schiano Dominick | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Stanwood Darren | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Dove Bryan | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Stanwood Darren | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lord Joanna | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Ahmad Shahraab | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ahmad Shahraab | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |